The HK1 Knockout HT29 Polyclonal Cells product comprises a polyclonal population of HT29 cells carrying CRISPR/Cas9-mediated disruption of the HK1 gene. This loss-of-function model is tailored for investigating hexokinase 1 (HK1) function in a colorectal adenocarcinoma background, offering a genetically diverse tool for functional genomics, drug screening, and metabolic research.
The HT29 host cell line is a well-established human colorectal adenocarcinoma model originally derived from a 44-year-old female Caucasian patient. These epithelial cells are widely used in cancer biology to study colorectal cancer signaling, metabolic reprogramming, and the Warburg effect. Their robust growth and compatibility with biochemical and cell-based assays make them an ideal platform for generating knockout models.
HK1 encodes hexokinase 1, a rate-limiting glycolytic enzyme that phosphorylates glucose to glucose-6-phosphate at the mitochondrial outer membrane through interaction with VDAC. Its activity is regulated by insulin, HIF-1??, AMPK, and mTOR signaling, integrating nutrient and growth factor cues. The resultant glucose-6-phosphate fuels glycolysis and the pentose phosphate pathway, providing ATP, NADPH, and ribose-5-phosphate. In the glycolytic cascade, HK1 operates upstream of PFKL and PKM2, with downstream conversion to lactate by LDHA. Disruption of HK1 in this polyclonal knockout population cripples glycolytic flux, compromises ATP and NADPH production, and impairs biosynthetic precursor supply, rendering cells susceptible to oxidative stress.
In HT29 cells, which display elevated glycolytic rates characteristic of the Warburg effect, HK1 knockout profoundly remodels energy metabolism. This model reflects the consequences of ablating a major hexokinase isoform in colorectal cancer, potentially limiting proliferation and increasing vulnerability to oxidative damage. Given that HT29 cells harbor mutations in APC, TP53, and KRAS, the knockout enables interrogation of genotype-specific metabolic dependencies. It also provides a system to investigate compensatory upregulation of HK2 and to dissect the role of mitochondrial hexokinase?CVDAC complexes in apoptosis regulation and bioenergetics.
Researchers can utilize this polyclonal HK1 knockout model for diverse metabolic and oncological studies. Typical assays include glucose uptake with 2-NBDG, lactate secretion quantification, ATP measurement, and Seahorse extracellular flux analysis to assess glycolytic and mitochondrial respiration. The cells are suitable for proliferation and colony formation assays, as well as flow cytometry for apoptosis, necrosis, and reactive oxygen species. Western blotting for HK1, PFKL, PKM2, and LDHA, combined with metabolomics profiling, can delineate compensatory metabolic rewiring. The model also supports drug screening for metabolic inhibitors and synthetic lethal interactions in colorectal cancer. For further technical details and product support, please contact Ascent Research.
